MED12 and cancer: Our study shows that PTs present temporal heterogeneity of MED12 mutation status (with consequences for potential targeted cancer therapies), that MED12 nuclear expression in the epithelial component of phyllodes tumors is associated with MED12-mutated tumors, and that, among all genomic alterations described in PTs, no alteration is significantly associated with MED12-WT tumors